Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate

Clinical Rheumatology

Volumn 34, Issue 4, 2015, Pages 807-809

  Lopalco, Giuseppe ^a   Rigante, Donato ^b   Vitale, Antonio ^c   Frediani, Bruno ^c   Iannone, Florenzo ^a   Cantarini, Luca ^c  

^a POLICLINICO   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Alendronate; Fever; Inflammation; Osteoporosis; Tumor necrosis factor receptor associated periodic syndrome (TRAPS)

Indexed keywords

ALENDRONIC ACID; CANAKINUMAB; ETANERCEPT; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; TNFRSF1A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; CASE REPORT; CHEMISTRY; DRUG COMBINATION; FEMALE; FEVER; GENETICS; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMAN; INFLAMMATION; METABOLISM; MUTATION; OSTEOPOROSIS; PHENOTYPE; RECURRENT DISEASE;

ADULT; ALENDRONATE; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; FEVER; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MUTATION; OSTEOPOROSIS; PHENOTYPE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECURRENCE;

EID: 84951014845     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2556-8     Document Type: Review

References (11)

1. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133–144
2. Cantarini L, Lucherini OM, Muscari I, Frediani B, Galeazzi M, Brizi MG et al (2012) Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 12:38–43
3. Cantarini L, Rigante D, Lucherini OM, Cimaz R, Laghi Pasini F, Baldari CT et al (2010) Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 23:701–707
4. Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F et al (2013) Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm 2013:939847
5. Brizi MG, Galeazzi M, Lucherini OM, Cantarini L, Cimaz R (2012) Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med 156:907–908
6. Romas E, Gillespie MT (2006) Inflammation-induced bone loss: can it be prevented? Rheum Dis Clin N Am 32:759–773
7. Bodar EJ, van der Hilst JC, van Heerde W, van der Meer JW, Drenth JP, Simon A (2007) Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood 109:2416–2418
8. Cantatore FP, Introsso AM, Carrozzo M (1996) Effects of bisphosphonates on interleukin 1, tumor necrosis factor alpha, and beta 2 microglobulin in rheumatoid arthritis. J Rheumatol 23:1117–1118
9. Sansoni P, Passeri G, Fagnoni F, Mohagheghpour N, Snelli G, Brianti V et al (1995) Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 10:1719–1725
10. Cantarini L, Rigante D, Merlini G, Vitale A, Caso F, Lucherini OM et al (2013) The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. Semin Arthritis Rheum. doi:10.1016/j.semarthrit.2013.12.002
11. Cantarini L, Vitale A, Magnotti F, Lucherini OM, Caso F, Frediani B, Galeazzi M, Rigante D (2013) Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis 8:196